Evidence map›Paper›PMID 31239639›Full record

ArticleDrug design, development and therapy2019

A novel non-invasive monitoring assay of 5-azacitidine efficacy using global DNA methylation of peripheral blood in myelodysplastic syndrome.

Michiyo Asano, Junko H Ohyashiki, Chiaki Kobayashi-Kawana, Tomohiro Umezu, Satoshi Imanishi, Kenko Azuma, Daigo Akahane, Hiroaki Fujimoto, Yoshikazu Ito, Kazuma Ohyashiki

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Drug design, development and therapy, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.5field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Michiyo AsanoDepartment of Hematology, Tokyo Medical University, Tokyo, Japan.
Junko H OhyashikiDepartment of Advanced Cellular Therapy, Tokyo Medical University, Tokyo, Japan.
Chiaki Kobayashi-KawanaDepartment of Hematology, Tokyo Medical University, Tokyo, Japan.
Tomohiro UmezuDepartment of Hematology, Tokyo Medical University, Tokyo, Japan.
Satoshi ImanishiDepartment of Molecular Oncology, Institute of Medical Science, Tokyo Medical University, Tokyo, Japan.
Kenko AzumaDepartment of Molecular Oncology, Institute of Medical Science, Tokyo Medical University, Tokyo, Japan.
Daigo AkahaneDepartment of Hematology, Tokyo Medical University, Tokyo, Japan.
Hiroaki FujimotoDepartment of Hematology, Tokyo Medical University, Tokyo, Japan.
Yoshikazu ItoDepartment of Hematology, Tokyo Medical University, Tokyo, Japan.
Kazuma OhyashikiDepartment of Hematology, Tokyo Medical University, Tokyo, Japan.
Tokyo Medical University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

AdultAgedAged, 80 and overAntimetabolites, AntineoplasticAzacitidineDNA MethylationFemaleHumansMaleMiddle AgedMyelodysplastic SyndromesSpectrometry, FluorescenceYoung AdultAntimetabolites, AntineoplasticAzacitidineazacytidinemethylation indexmyelodysplastic syndromeperipheral blood

Identifiers

PMID31239639
PMCPMC6553951
OpenAlexW2947390387

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.